Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
28582 | 204 | 25.2 | 55% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
535 | 3 | TAURINE//CHRONIC GRANULOMATOUS DISEASE//L FORMS | 19480 |
1929 | 2 | TAURINE//MYELOPEROXIDASE//HYPOCHLOROUS ACID | 5796 |
28582 | 1 | TAUROLIDINE//DUODENOCAVAL FISTULA//DUODENAL CAVAL FISTULA | 204 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | TAUROLIDINE | authKW | 4453797 | 26% | 55% | 54 |
2 | DUODENOCAVAL FISTULA | authKW | 598734 | 2% | 100% | 4 |
3 | DUODENAL CAVAL FISTULA | authKW | 449050 | 1% | 100% | 3 |
4 | TAUROLIN | authKW | 399153 | 2% | 67% | 4 |
5 | TAURULTAM | authKW | 299367 | 1% | 100% | 2 |
6 | 5 BROMO 4 CHLORO 3 INDOLYL BETA D GALACTOSIDE X GAL STAINING | authKW | 149683 | 0% | 100% | 1 |
7 | ANGIOGENESIS VEGF CD31 | authKW | 149683 | 0% | 100% | 1 |
8 | ANTIBACTERIAL AGENT TAUROLIDINE | authKW | 149683 | 0% | 100% | 1 |
9 | ANTIOXIDANT TAURINE | authKW | 149683 | 0% | 100% | 1 |
10 | APOPTOSIS TNF ALPHA AND CASPAS 3 | authKW | 149683 | 0% | 100% | 1 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Surgery | 596 | 30% | 0% | 61 |
2 | Oncology | 279 | 21% | 0% | 42 |
3 | Pharmacology & Pharmacy | 222 | 21% | 0% | 43 |
4 | Urology & Nephrology | 52 | 5% | 0% | 11 |
5 | Gastroenterology & Hepatology | 38 | 5% | 0% | 10 |
6 | Chemistry, Medicinal | 23 | 4% | 0% | 8 |
7 | Microbiology | 18 | 5% | 0% | 11 |
8 | Respiratory System | 16 | 3% | 0% | 6 |
9 | Pathology | 8 | 2% | 0% | 5 |
10 | Critical Care Medicine | 7 | 1% | 0% | 3 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | CHARITE BERLINCCM | 149683 | 0% | 100% | 1 |
2 | CHARITECCM | 149683 | 0% | 100% | 1 |
3 | HAND BURN | 149683 | 0% | 100% | 1 |
4 | MED CHARITEUNIV MED BERLIN | 149683 | 0% | 100% | 1 |
5 | PLAST SURGHAND | 149683 | 0% | 100% | 1 |
6 | PLAST SURGHAND SARCOMA REFERENCE | 149683 | 0% | 100% | 1 |
7 | SURG PUBL HLTH CRIT CARE TRAUMA | 149683 | 0% | 100% | 1 |
8 | GEN VISCERAL VASC THORAC SURG | 113422 | 6% | 6% | 12 |
9 | SARCOMA REFERENCE | 103938 | 2% | 14% | 5 |
10 | MOL GASTROINTESTINAL ONCOL | 89805 | 1% | 20% | 3 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JOURNAL OF CLINICAL AND HOSPITAL PHARMACY | 21457 | 3% | 2% | 6 |
2 | DRUG & COSMETIC INDUSTRY | 7874 | 1% | 3% | 2 |
3 | LANGENBECKS ARCHIV FUR CHIRURGIE | 2835 | 3% | 0% | 6 |
4 | PHARMATHERAPEUTICA | 1897 | 1% | 1% | 2 |
5 | HELVETICA CHIRURGICA ACTA | 1344 | 1% | 0% | 3 |
6 | PHARMACY INTERNATIONAL | 1193 | 1% | 0% | 2 |
7 | EUROPEAN SURGICAL RESEARCH | 726 | 1% | 0% | 3 |
8 | AKTUELLE CHIRURGIE | 691 | 0% | 0% | 1 |
9 | CLINICAL & EXPERIMENTAL METASTASIS | 670 | 1% | 0% | 3 |
10 | JOURNAL OF INVESTIGATIVE SURGERY | 664 | 1% | 0% | 2 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | MOHLER, H , PFIRRMANN, RW , FREI, K , (2014) REDOX-DIRECTED CANCER THERAPEUTICS: TAUROLIDINE AND PIPERLONGUMINE AS BROADLY EFFECTIVE ANTINEOPLASTIC AGENTS.INTERNATIONAL JOURNAL OF ONCOLOGY. VOL. 45. ISSUE 4. P. 1329 -1336 | 36 | 59% | 5 |
2 | NEARY, PM , HALLIHAN, P , WANG, JH , PFIRRMANN, RW , BOUCHIER-HAYES, DJ , REDMOND, HP , (2010) THE EVOLVING ROLE OF TAUROLIDINE IN CANCER THERAPY.ANNALS OF SURGICAL ONCOLOGY. VOL. 17. ISSUE 4. P. 1135 -1143 | 34 | 52% | 13 |
3 | CHROMIK, AM , DAIGELER, A , BULUT, D , FLIER, A , MAY, C , HARATI, K , ROSCHINSKY, J , SULBERG, D , RITTER, PR , MITTELKOTTER, U , ET AL (2010) COMPARATIVE ANALYSIS OF CELL DEATH INDUCTION BY TAUROLIDINE IN DIFFERENT MALIGNANT HUMAN CANCER CELL LINES.JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. VOL. 29. ISSUE . P. - | 25 | 71% | 6 |
4 | LUCKERT, C , ESCHENBURG, G , ROTH, B , APPL, B , REINSHAGEN, K , BERGHOLZ, R , (2014) TAUROLIDINE SPECIFICALLY INHIBITS GROWTH OF NEUROBLASTOMA CELL LINES IN VITRO.JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY. VOL. 36. ISSUE 4. P. E219-E223 | 19 | 79% | 0 |
5 | ABRAMJUK, C , BUESCHGES, M , SCHNORR, J , JUNG, K , STAACK, A , LEIN, M , (2009) DIVERGENT EFFECTS OF TAUROLIDINE AS POTENTIAL ANTI-NEOPLASTIC AGENT: INHIBITION OF BLADDER CARCINOMA CELLS IN VITRO AND PROMOTION OF BLADDER TUMOR IN VIVO.ONCOLOGY REPORTS. VOL. 22. ISSUE 2. P. 409-414 | 24 | 69% | 7 |
6 | STENDEL, R , SCHEURER, L , SCHLATTERER, K , STALDER, U , PFIRRMANN, RW , FISS, I , MOHLER, H , BIGLER, L , (2007) PHARMACOKINETICS OF TAUROLIDINE FOLLOWING REPEATED INTRAVENOUS INFUSIONS MEASURED BY HPLC-ESI-MS/MS OF THE DERIVATIVES TAURULTAME AND TAURINAMIDE IN GLIOBLASTOMA PATIENTS.CLINICAL PHARMACOKINETICS. VOL. 46. ISSUE 6. P. 513-524 | 18 | 86% | 11 |
7 | GONG, L , GREENBERG, HE , PERHACH, JL , WALDMAN, SA , KRAFT, WK , (2007) THE PHARMACOKINETICS OF TAUROLIDINE METABOLITES IN HEALTHY VOLUNTEERS.JOURNAL OF CLINICAL PHARMACOLOGY. VOL. 47. ISSUE 6. P. 697-703 | 16 | 94% | 13 |
8 | HARATI, K , EMMELMANN, S , BEHR, B , GOERTZ, O , HIRSCH, T , KAPALSCHINSKI, N , KOLBENSCHLAG, J , STRICKER, I , TANNAPFEL, A , LEHNHARDT, M , ET AL (2016) EVALUATION OF THE SAFETY AND EFFICACY OF TRAIL AND TAUROLIDINE USE ON HUMAN FIBROSARCOMA XENOGRAFTS IN VIVO.ONCOLOGY LETTERS. VOL. 11. ISSUE 3. P. 1955 -1961 | 22 | 55% | 0 |
9 | IMHOF, L , GOLDINGER, SM , BAUMANN, K , SCHAD, K , FRENCH, LE , ROTHLISBERGER, P , DUMMER, R , (2011) THE ANTIBACTERIAL SUBSTANCE, TAUROLIDINE IN THE SECOND/THIRD-LINE TREATMENT OF VERY ADVANCED STAGE IV MELANOMA INCLUDING BRAIN METASTASES: RESULTS OF A PHASE 2, OPEN-LABEL STUDY.MELANOMA RESEARCH. VOL. 21. ISSUE 1. P. 80 -83 | 16 | 80% | 2 |
10 | CHROMIK, AM , HAHN, SA , DAIGELER, A , FLIER, A , BULUT, D , MAY, C , HARATI, K , ROSCHINSKY, J , SULBERG, D , WEYHE, D , ET AL (2010) GENE EXPRESSION ANALYSIS OF CELL DEATH INDUCTION BY TAUROLIDINE IN DIFFERENT MALIGNANT CELL LINES.BMC CANCER. VOL. 10. ISSUE . P. - | 25 | 43% | 6 |
Classes with closest relation at Level 1 |